Vienna-based startup aTENSION.life has launched to innovate hypertension treatment using its ALDO+ technology platform, securing $3M in funding. The company aims to address the vast market of 1.3 billion adults affected by hypertension, many of whom are undiagnosed. Current diagnostic methods are ineffective, causing delays in treatment. Their first product, the ALDO+PA test, is designed to enable early diagnosis of conditions like primary aldosteronism, improving treatment outcomes through more precise diagnostics accessible to all patients, thereby reducing cardiovascular risks associated with hypertension.
With about 1.3B adults affected by hypertension and 720M not receiving the treatment they need, we address a vast and urgent market.
This funding brings us one step closer to making clinical mass spectrometry diagnostics available to everyone.
Collection
[
|
...
]